Huadong Medicine vs McKesson: why the prices moved differently

• ▼

  Procurement loss threatens core revenue Huadong lost bids for four products, including core indobufen tablets, with 2025 sales of 4.634 billion yuan — 10.62% of total revenue. Losing hospital access will likely cut future sales, a real drag on the stock.

  This is the biggest negative force this period, directly threatening a large chunk of revenue.

• ▲

  Aesthetic products gain China and EU approvals Huadong's subsidiary won EU CE certification for an injectable aesthetic product and China approval for MaiLi Precise, the first injectable for under-eye hollows. These open new markets and support future growth, though near-term financial impact is small.

  New product approvals are a positive growth driver that can lift investor sentiment.

• ▲

  FDA fast track for innovative cancer drug HDM2005, a first-in-class ROR1-targeting ADC for mantle cell lymphoma, received FDA Fast Track designation. This speeds up development and review, boosting the company's innovative drug story and long-term potential.

  A regulatory win for a novel cancer drug adds credibility and future revenue potential.

• ◆

  Interim profit up but quarterly slowdown First-half net profit rose 2.53% to 1.861 billion yuan, with a 3.5 yuan per 10 shares dividend. But second-quarter profit fell 14% from the first quarter, and margins weakened, so the market may worry about momentum.

  The earnings report is the key financial update, showing both stability and a concerning quarterly decline.

Based on 9 stories →

• ▲

  Raised fiscal 2027 EPS guidance on broad-based growth McKesson lifted its full-year adjusted EPS guidance to $44.20–$45.00, implying 15–17% growth, after Q1 revenue rose 8% and adjusted EPS climbed 20%. Higher expected profits make the stock more attractive to investors.

  This is the core new event that directly raises profit expectations and pushes the stock up.

• ▲

  Oncology and GLP-1 distribution surge Oncology and multispecialty revenue jumped 33% to $14.2 billion, and GLP-1 distribution revenue reached $15 billion, up about 24% year over year. These fast-growing areas are becoming a bigger part of McKesson's business, supporting higher profits and a higher stock price.

  This explains the underlying demand strength that is driving the guidance raise and future growth.

• ▲

  CVS Health distribution deal extended through June 2032 McKesson signed an agreement in principle to extend its drug distribution partnership with CVS Health through June 2032, building on a 25-year relationship. The extension locks in a major customer, giving investors more confidence in steady future revenue.

  This is a new, concrete event that secures long-term demand and supports the stock.

• ▲

  Option Care Health acquisition for $1.4 billion stake McKesson agreed to invest $1.4 billion for a 49% stake in Option Care Health, a home infusion provider, as part of a $5.8 billion deal with CD&R. This expands McKesson's reach into home care, a growing area, and signals strategic investment that could add future earnings.

  This is a new M&A event that expands McKesson's business and is a key driver of recent stock movement.

Based on 7 stories →

• ▲

  Raised fiscal 2027 guidance on broad-based growth McKesson raised full-year adjusted EPS guidance to $44.20–$45.00, implying 13–15% growth, after first-quarter results beat expectations. Three of four segments posted double-digit growth, led by oncology and prescription technology. This directly lifts investor expectations for future profits, pushing the stock up.

  This is the core new positive event that answers why MCK is moving right now.

• ▲

  Oncology and GLP-1 distribution surge Oncology & Multispecialty revenue jumped 33% to $14.2 billion with operating profit up 41%, while GLP-1 distribution revenue reached $15 billion, up 24% year over year. These high-growth areas are becoming a bigger part of McKesson's business, supporting higher profits and a higher stock price.

  It explains the fundamental growth engine behind the raised guidance and investor optimism.

• ▲

  Acquisition of Precision Medicine Group for $2.25 billion McKesson agreed to buy Precision Medicine Group, a clinical research and biopharma services provider, for about $2.25 billion. The deal expands its higher-growth oncology and specialty services. While modest in size, it signals continued strategic investment that could add future earnings, supporting the stock.

  This is a new strategic move that investors are evaluating as a driver of future growth.

• ▼

  Branded drug price cuts and integration risks persist Price reductions by branded manufacturers cut North American Pharmaceutical revenue growth by about 3 percentage points and are expected to continue through fiscal 2027. Acquisition integration and unpredictable Prescription Technology Solutions performance also pose risks. These pressures can limit profit growth and weigh on the stock.

  It provides the necessary counterweight, showing real headwinds that could offset positive drivers.

Based on 6 stories →